Drugs that target the amyloid beta protein in the brain increase the risk of bleeding and swelling in the brain and are likely to have no clinically meaningful positive effects, a new Cochrane review has found.
Alzheimer’s patients have high concentrations of a protein known as amyloid beta in their brains and can be detected before symptoms begin, but the role of amyloid beta in the progression of the disease is unknown. Drugs have been developed on the theory that removing these proteins from the brain can prevent or slow disease progression.
The new review examined data from 17 clinical trials involving a total of 20,342 people, all examining the effects of anti-amyloid drugs on people with mild cognitive impairment or mild dementia caused by Alzheimer’s disease. Proponents of these drugs theorize that they are more effective in the early stages, before the disease progresses.
Absolute efficacy is “well below the clinical threshold”
This study found that the absolute effect of anti-amyloid drugs on cognitive decline and dementia severity was absent or small, well below the threshold established as the minimum clinically important difference.
“Unfortunately, the evidence suggests that these drugs do not produce significant changes in patients,” says lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neuroscience in Bologna, Italy.
There is now a convincing body of evidence converging on the conclusion that there are no clinically meaningful effects. Although early trials have shown statistically significant results, it is important to distinguish this from clinical relevance. Clinical trials often yield statistically significant results that do not translate into meaningful clinical differences for patients. ”
Francesco Nonino, IRCCS Institute of Neuroscience
In addition to the lack of clinically meaningful effects, the review found that anti-amyloid drugs are likely to increase the risk of brain swelling and bleeding. This was observed in brain scans, and most patients had no obvious symptoms, but the long-term effects remain unclear because reporting of symptoms was inconsistent across trials.
Future research should focus on other pathways
Based on the evidence, the authors conclude that future trials targeting amyloid beta removal are unlikely to provide clear benefit to patients. They found that these drugs were successful in removing amyloid proteins from the brain, but this did not translate into meaningful clinical benefit. They recommend that future research on Alzheimer’s disease treatment should focus on other mechanisms, and that much research is underway in other directions.
“I see patients with Alzheimer’s disease every week in the clinic, and I wish we could provide them with an effective treatment,” said lead author Ed Richard, professor of neurology at Radboud University Medical Center. “While existing approved drugs provide some benefit for some patients, there remains a high unmet need for more effective treatments. Unfortunately, anti-amyloid drugs do not provide this and come with additional risks. Given the lack of correlation between amyloid clearance and clinical benefit, we need to explore other routes to help address this devastating disease.”
sauce:
Reference magazines:
Nonino, F. others. (2026). A monoclonal antibody targeting amyloid beta for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.cd016297. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016297/full.
